NTLA FY2027 EPS Lifted by Brookline Capital Management

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at Brookline Capital Management raised their FY2027 EPS estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of $22.48 per share for the year, up from their previous forecast of $22.30. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Brookline Capital Management also issued estimates for Intellia Therapeutics’ FY2028 earnings at $47.65 EPS and FY2029 earnings at $95.29 EPS.

A number of other equities research analysts have also recently issued reports on the company. Oppenheimer reduced their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a report on Monday, January 13th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday. William Blair reissued a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Morgan Stanley cut shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $42.12.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $10.09 on Monday. Intellia Therapeutics has a 52 week low of $8.96 and a 52 week high of $34.87. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -1.85 and a beta of 1.80. The company has a 50-day simple moving average of $10.85 and a 200 day simple moving average of $15.59.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. GF Fund Management CO. LTD. bought a new stake in shares of Intellia Therapeutics during the fourth quarter worth $25,000. Sterling Capital Management LLC boosted its holdings in shares of Intellia Therapeutics by 866.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC bought a new stake in Intellia Therapeutics during the 4th quarter worth $40,000. Resona Asset Management Co. Ltd. acquired a new position in Intellia Therapeutics in the 4th quarter worth about $43,000. Finally, Jones Financial Companies Lllp raised its position in Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after purchasing an additional 2,280 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last quarter, insiders sold 29,000 shares of company stock valued at $352,551. Corporate insiders own 3.20% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.